Day: January 7, 2022

Philogen announces publication of PET clinical data with proprietary ultra-high affinity FAP-targeting small molecule ligand (OncoFAP) Translational studies performed at the European Institute for Molecular Imaging and the Department of Nuclear Medicine (University and University Hospital of Münster) show rapid and selective tumor uptake of OncoFAP with unprecedented selectivity against healthy organs in cancer patients Philogen, in collaboration with Senn Chemicals, has already produced the equivalent of 1 million GMP doses of clinical-grade OncoFAP-DOTAGA Siena, Italy, January 7th, 2022 – Philogen S.p.A., a clinical-stage biotechnology company focused on antibody and small molecule-based targeted therapeutics, announces that its wholly-owned Swiss subsidiary, Philochem AG, has co-authored a new translational study on 68Ga-OncoFAP,...

The Hague, January 7, 2022 – Aegon announced today that it will repurchase common shares for an amount of EUR 50 million to meet its obligations resulting from the 2021 and 2022 share-based compensation plans for senior management. The repurchased shares will be held as treasury shares until they are allocated to the plan participants. The repurchase of shares will commence on January 7, 2022 and is expected to be completed on or before January 28, 2022. Aegon will engage a third party to execute the transactions on its behalf. The common shares will be repurchased at a maximum of the average of the daily volume-weighted average prices during the repurchase period. Weekly updates regarding the transactions will be available on aegon.com. About Aegon Aegon’s roots go back more than 175 years – to the first half of the nineteenth century....

Contacts Media Contact Investor RelationsAmsterdam +31 20 721 4133 Brussels +32 2 620 15 50 +33 1 70 48 24 27Dublin +353 87 361 2380 Lisbon +351 210 600 614  Milan +39 02 72 42 62 12 Oslo +47 41 69 59 10  Paris +33 1 70 48 24 45      Half-year statement of the liquidity contract of Euronext NV          Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 7 January 2022 – Euronext announced today that the transactions carried out under the liquidity contract entered between Euronext NV and Rothschild Martin Maurel for the period ending 31 December 2021 resulted in the following assets appearing in the liquidity account:0 Euronext NV shares 7,616,927 euros Number of Buy transaction over the period: 3,509 Number of Sell transaction over the period: 3,636 Volume traded...

Montrouge, France, January 7, 2022 DBV Technologies to Present at the H.C. Wainwright BioConnect 2022 Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference. The fireside chat will be available for on-demand viewing starting Monday, January 10, 2022, at 7:00am ET. A webcast of the fireside chat will be available on the News & Resources section of the Company’s website: https://www.dbv-technologies.com/news-and-resources/ A replay of the fireside chat will also be available on DBV Technologies’ website after the event. About DBV TechnologiesDBV Technologies is developing Viaskin™, an investigational proprietary...

Ad hoc announcement pursuant to Art. 53 LR Basel, Switzerland, January 07, 2022 Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced today that sales of the antifungal Cresemba® (isavuconazole) by its partner Astellas Pharma Inc. (“Astellas”) in the United States exceeded the threshold triggering a milestone payment to Basilea of CHF 15 million. David Veitch, Chief Executive Officer of Basilea, said: “We are very pleased with the continued commercial success of Cresemba. This significant milestone payment reflects the strong sales growth in 2021 in the U.S. and confirms the important role that Cresemba plays in the treatment of patients suffering from invasive mold infections.” Under the license agreement with Astellas,...

Completed Patient Enrollment for Part A of Phase 2 INTEGRAL Trial Evaluating THR-687 for treatment of Diabetic Macular Edema (DME) in treatment naïve subjects US IRB Approval of Protocol Amendment to Part B of the Phase 2 KALAHARI Trial Assessing THR-149 versus aflibercept for treatment of DME in patients that suboptimally respond to anti-VEGF therapy Full dataset from Part A of KALAHARI Trial to be presented at Angiogenesis on February 12th Leuven, BELGIUM, Boston, MA, US – 7 January 2022 – 7.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in vascular retinal disorders, today announced updates on its two clinical programs, THR-687, initially being developed for first line treatment of DME, and THR-149 being developed...

Amsterdam, 7 January 2022 — AMG Advanced Metallurgical Group N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) is hosting a Capital Markets Day spotlighting AMG Lithium, which will be held virtually on January 11, 2022 at 10am EST. The presenters will include AMG’s CEO, Dr. Heinz Schimmelbusch, as well as AMG Lithium’s Managing Directors, Dr. Stefan Scherer and Mr. Fabiano Costa. To attend the event, participants should register using the following link: https://amg.eventcube.io/ For more information on this event, please see the Capital Markets Day flyer on the homepage of AMG’s website. About AMG AMG is a global critical materials company at the forefront of CO2 reduction trends. AMG produces highly engineered specialty metals and mineral products and provides related vacuum furnace systems and services to the transportation,...

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced the pricing of its initial public offering of 12,100,000 shares of common stock at a price to the public of $16.00 per share. The gross proceeds to CinCor from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $193.6 million. All of the shares are being offered by CinCor. In addition, CinCor has granted the underwriters a 30-day option to purchase up to an additional 1,815,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions. The shares...

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the pricing of its initial public offering of 7,000,000 shares of its common stock at a price to the public of $14.00 per share. All of the shares are being offered by Vigil Neuroscience. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Vigil Neuroscience, are expected to be $98.0 million. In addition, the underwriters have a 30-day option to purchase up to 1,050,000 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin...